Akari Therapeutics Plc
AKTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001541157
No open-market purchases or sales by Akari Therapeutics Plc insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.54M in total; no superinvestor holds it.
Holders of 5% or more of AKTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Akari Therapeutics Plc, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Huh Hoyoung | 13G/A | 18.40%18.2B shares | +2.90 ppfrom 15.50% | Feb 14, 20252 filings | Mar 4, 2026 | SEC |
| Patel Samir Rashmikant | 13D/A | 10.40%9.73B shares | – | Feb 16, 20216 filings | Mar 4, 2026 | SEC |
| Prudo-Chlebosz Raymond | 13D/A | 8.90%8.39B shares | −0.40 ppfrom 9.30% | Feb 14, 20252 filings | Mar 4, 2026 | SEC |
| MMCAP International Inc. SPC | 13G | 8.00%8.00B shares | New | Jun 8, 20261 filing | Jun 8, 2026 | SEC |
| Bank of Montreal | 13G | 5.71%8.00B shares | New | Aug 12, 20261 filing | Aug 12, 2026 | SEC |
| White Lion Capital LLC | 13G | 5.00%7.00B shares | New | Aug 7, 20261 filing | Aug 7, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
20 Schedule 13D and 13G filings on Akari Therapeutics Plc, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 12, 202611:03 AM ET | Bank of Montrealand 2 others | 13G | 5.71%8.00B shares | New | Jun 30, 2026 | SEC |
| Aug 7, 20266:51 PM ET | White Lion Capital LLC | 13G | 5.00%7.00B shares | New | Aug 7, 2026 | SEC |
| Jun 8, 20268:53 PM ET | MMCAP International Inc. SPCand 1 other | 13G | 8.00%8.00B shares | New | Jun 2, 2026 | SEC |
| Mar 4, 20264:52 PM ET | Prudo-Chlebosz Raymondand 2 others | 13D/A | 8.90%8.39B shares | −0.40 ppfrom 9.30% | Mar 2, 2026 | SEC |
| Mar 4, 20264:44 PM ET | Patel Samir Rashmikant | 13D/A | 10.40%9.73B shares | – | Mar 2, 2026 | SEC |
| Mar 4, 20264:44 PM ET | Huh Hoyoung | 13G/A | 18.40%18.2B shares | +2.90 ppfrom 15.50% | Mar 2, 2026 | SEC |
| Feb 14, 20255:00 PM ET | Huh Hoyoung | 13G | 15.50%8.29B shares | New | Nov 14, 2024 | SEC |
| Feb 14, 20255:00 PM ET | Prudo-Chlebosz Raymondand 2 others | 13D/A | 9.30%4.93B shares | – | Nov 14, 2024 | SEC |
| Dec 6, 2024 | Patel Samir Rashmikant | 13D/AOld format | – | – | – | SEC |
| Jun 20, 2024 | RPC Pharma Ltd | 13D/AOld format | – | – | – | SEC |
| Jun 18, 2024 | Theofilos Charles Steve | 13DOld format | – | New | – | SEC |
| Jun 7, 2024 | Patel Samir Rashmikant | 13DOld format | – | – | – | SEC |
| Jan 4, 2024 | RPC Pharma Ltd | 13D/AOld format | – | – | – | SEC |
| Oct 20, 2023 | RPC Pharma Ltd | 13D/AOld format | – | – | – | SEC |
| Apr 14, 2023 | RPC Pharma Ltd | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Patel Samir Rashmikant | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Patel Samir Rashmikant | 13G/AOld format | – | – | – | SEC |
| Jan 14, 2022 | RPC Pharma Ltd | 13D/AOld format | – | – | – | SEC |
| Oct 18, 2021 | RPC Pharma Ltd | 13D/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Patel Samir Rashmikant | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Akari Therapeutics Plc shares.
No Form 144 notices for Akari Therapeutics Plc are on file.